Psoriasis is an incurable skin disease that develops in about two-thirds of patients before the
age of 40 and requires lifelong treatment; its pathological mechanisms have not been fully …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Simple Summary Atherosclerosis is a critical cardiovascular disease associated with the use
of immune checkpoint inhibitors (ICIs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Fibroblasts are critical pro-inflammatory regulators in chronic inflammatory and fibrotic skin
diseases. However, fibroblast heterogeneity and the absence of a unified cross-disease …

IL-36 is a most recent member of the IL-1 cytokine family, primarily expressed at barrier sites
of the body such as the skin, lungs, and intestine. It plays a vital role in inflammation and is …

The barrier function of skin epidermis is crucial for our bodies to interface with the
environment. Because epidermis continuously turns over throughout the lifetime, this barrier …

In recent years, genome-wide association studies (GWAS) have been instrumental in
unraveling the genetic architecture of complex diseases, including psoriasis. The application …

Psoriasis comorbidities may emerge from pleiotropic mechanisms, including common
proinflammatory pathways, cellular mediators or genetic predisposition. Obesity is …

Neutrophil gelatinase-associated lipocalin (NGAL) may promote development of
inflammation in psoriasis, whereas proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Atopic dermatitis (AD), a complex and heterogeneous chronic inflammatory skin disorder,
manifests in a spectrum of clinical subtypes. The application of genomics has elucidated the …